Shandong Weigao repurchases shares, boosting treasury holdings

Shandong Weigao Group Medical Polymer Company Limited reported a repurchase of 100,000 H shares on November 13, 2025. This decreased issued shares (excluding treasury shares) by 100,000, representing 0.0022% of existing issued shares before the event. Concurrently, the number of treasury shares increased by 100,000.

The shares were repurchased on the exchange at prices ranging from HK$5.49 to HK$5.52 per share, with a volume-weighted average price of HK$5.506, totaling an aggregate cost of HK$550,600. Following this transaction, the company’s closing balance of issued shares (excluding treasury shares) stands at 4,497,822,324, and treasury shares are at 24,510,000. The total number of issued shares remains unchanged at 4,522,332,324.

The repurchase was executed under a mandate granted on May 27, 2025, which authorized the company to repurchase a total of 451,560,392 shares. To date, 17,861,600 shares have been repurchased on the exchange, representing 3.9556% of the issued shares (excluding treasury shares) as of the mandate date. A moratorium period for new share issues or treasury share sales is in effect until December 12, 2025.